Intuitive Surgical, Inc.
537.59-7.80 (-1.43%)
Oct 29, 4:00:01 PM EDT · NasdaqGS · ISRG · USD
Key Stats
Market Cap
190.57BP/E (TTM)
70.92Basic EPS (TTM)
7.58Dividend Yield
0%Recent Filings
8-K
Q3 revenue surges 23%
Intuitive Surgical reported Q3 2025 revenue of $2.51 billion, up 23% from $2.04 billion last year, fueled by 19% da Vinci procedure growth and 52% Ion surge, alongside 427 system placements including 240 da Vinci 5 units. GAAP net income hit $704 million, or $1.95 per diluted share, while non-GAAP reached $867 million, or $2.40 per share—reconciled in the filing. Tariffs pressure margins to 67-67.5% for 2025. Strong adoption drives expansion, yet supply risks loom.
10-Q
Q2 FY2025 results
Intuitive Surgical's Q2 revenue climbed 21% year-over-year to $2.44B, fueled by 17% procedure growth and 28% higher systems sales from 395 placements, including 180 da Vinci 5 units; instruments and accessories rose 18% to $1.47B while gross margins dipped to 66.3% amid launch costs and tariffs. Operating income surged 31% to $743M, with diluted EPS at $1.81 (up 24% y/y, derived), backed by a 14% larger installed base of 10,488 systems. Cash swelled to $3.4B and investments to $6.1B, yielding $1.30B operating cash flow for the half-year, though $181M stock repurchases trimmed liquidity. Yet tariffs loom large. Procedure adoption thrives.
8-K
Q2 revenue surges 21%
Intuitive Surgical reported Q2 revenue of $2.44 billion, up 21% from last year, fueled by 17% growth in da Vinci procedures and 395 system placements, including 180 da Vinci 5 units. The installed base hit 10,488 systems, boosting recurring instruments and accessories sales to $1.47 billion. GAAP net income rose to $658 million. Tariffs could materially dent 2025 gross margins.
8-K
Intuitive Surgical CEO transition
Intuitive Surgical announced on May 14, 2025, that President David J. Rosa will succeed Gary S. Guthart as CEO effective July 1, 2025, with Guthart transitioning to executive chair and remaining in a senior advisory role. Rosa, a 29-year veteran who joined as the ninth employee, brings deep expertise in engineering, product development, and strategy, including leading the da Vinci SP and Ion systems. This succession bolsters continuity while positioning Rosa to advance minimally invasive care innovations. Smooth transition expected amid regulatory and market risks.
8-K
Stockholders approve plan amendment
Intuitive Surgical's stockholders approved the amended 2010 Incentive Award Plan on May 1, 2025, boosting shares reserved for awards from 115.35 million to 120.35 million and extending the plan to 2035, while clarifying change-in-control treatments. All eleven board nominees were elected, executive pay was ratified, and the auditor appointment passed, but two shareholder proposals failed. The board then hiked the stock repurchase authorization to $4.0 billion total. This bolsters talent retention amid growth, yet repurchases hinge on market volatility.
IPO
Website
Employees
Sector
Industry
BDX
Becton, Dickinson and Company
181.52-2.69
ECIA
Encision, Inc.
0.35+0.12
HOLX
Hologic, Inc.
73.98-0.03
IART
Integra LifeSciences Holdings C
15.43-0.13
ICUI
ICU Medical, Inc.
117.67-2.44
MMSI
Merit Medical Systems, Inc.
81.39-1.40
RBOT
Vicarious Surgical Inc.
5.45-0.30
SOLV
Solventum Corporation
69.78-1.14
SSII
SS Innovations International In
8.65+0.13
STXS
Stereotaxis, Inc.
2.92-0.05